Efficacy of darinaparsin for EBV-associated B-cell lymphoma in a heavily treated elderly patient with angioimmunoblastic T-cell lymphoma: a case report.

This article discusses the use of darinaparsin, a new arsenic-based agent, in the treatment of Epstein-Barr virus (EBV)-associated B-cell lymphoma in an elderly patient with angioimmunoblastic T-cell lymphoma (AITL). The patient initially responded to chemotherapy but relapsed and progressed despite multiple treatment regimens. Darinaparsin was then administered and resulted in a partial response with reduced levels of EBV DNA. The article suggests that darinaparsin may be a potential treatment option for refractory EBV-associated B-cell lymphoma, particularly in frail patients. However, further research is needed to determine its efficacy in this specific subtype of lymphoma. The document is a consent form and disclosure statement for a research study conducted by Daisuke Ikeda, Mitsuaki Oura, Atsushi Uehara, Rikako Tabata, Kentaro Narita, Masami Takeuchi, and Kosei Matsue, and the patient involved in the study provided informed consent. The authors declare no competing interests. [Extracted from the article]